What is the mechanism of action of this treatment?

Common treatments for solid tumors include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy kills rapidly dividing cells, including cancer cells, while targeted therapies inhibit tumor growth by focusing on specific molecular targets such as proteins or genes. Immunotherapy, such as pembrolizumab, boosts the body's immune system to recognize and destroy cancer cells. These mechanisms are vital for solid tumor patients as they provide diverse strategies to combat cancer, potentially improving treatment efficacy and allowing for more personalized approaches.

What side effects are associated with this type of intervention?

Common treatments for solid tumors, such as chemotherapy and immunotherapy, have a range of side effects. Chemotherapy can cause myelosuppression, leading to anemia, neutropenia, and thrombocytopenia, as well as gastrointestinal issues like nausea, vomiting, and diarrhea. Other side effects include fatigue, hair loss, and increased risk of infections. Immunotherapy, including agents like pembrolizumab, can lead to immune-related adverse events such as pneumonitis, colitis, hepatitis, endocrinopathies, and skin reactions. Specific side effects of NDI-101150 are not detailed, but it is important to monitor for both common and severe reactions when undergoing treatment.

What prior FDA approvals exist?

The FDA has approved several drugs for the treatment of solid tumors, particularly focusing on immunotherapy and targeted therapy. Pembrolizumab, an anti-PD-1 antibody, is approved for various solid tumors, including non-small cell lung cancer and melanoma. Atezolizumab, another immune checkpoint inhibitor targeting PD-L1, is approved for non-small cell lung cancer and renal cell carcinoma. Additionally, combination therapies such as pembrolizumab with chemotherapy have shown efficacy in treating advanced solid tumors. These approvals highlight the trend towards using immunotherapy and combination regimens in the management of solid tumors.

What other types of research exist?

Promising novel alternatives to NDI-101150 for solid tumor patients include: 1) Pembrolizumab, an immune checkpoint inhibitor, which has shown efficacy in combination with chemotherapy for non-small-cell lung cancer and other solid tumors. 2) IdB 1016, a silybin-phosphatidylcholine complex, which is being evaluated for its antiangiogenic activity in ovarian cancer. 3) Atezolizumab, another immune checkpoint inhibitor, used in combination with chemotherapy for non-small-cell lung cancer. 4) Nivolumab, often combined with ipilimumab, showing promise in various solid tumors including renal cell carcinoma and gliomas. These alternatives are in various stages of clinical trials and have shown potential in treating solid tumors.

← Back to Search

Other

NDI-101150 + Pembrolizumab for Cancer

Phase 1 & 2

Recruiting

Research Sponsored by Nimbus Saturn, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

For Dose Escalation Phase Only (Dose Escalation, Monotherapy and Combination Therapy): Histologically or cytologically confirmed advanced or metastatic solid tumors for whom no standard therapies are available or refractory to standard therapy

For Dose Expansion Phase (Dose Expansion, Monotherapy and Combination Therapy): Willing to consent to required tumor biopsy(ies). Histologically or cytologically confirmed advanced or metastatic G/GEJ, NSCLC or RCC for which no standard therapy is available or are refractory to standard therapy

Timeline

Screening 28 days

Treatment 6 months

Follow Up 3 months

Awards & highlights

Study Summary

This trial is testing a new cancer drug to see what dose is safe and how well it works.

Who is the study for?

This trial is for adults with advanced solid tumors who have a life expectancy of at least 12 weeks, are willing to undergo tumor biopsies if needed, and have recovered from previous therapies. They should not have had cancer treatment in the last 4 weeks and must be in good physical condition (ECOG status 0-1). People with recent malignancies, severe allergies to monoclonal antibodies, untreated brain cancers, significant heart or lung conditions, or uncontrolled medical issues cannot join.Check my eligibility

What is being tested?

The study aims to find the safest high dose (MTD) and best Phase 2 dose (RP2D) of NDI-101150 alone or combined with pembrolizumab. It will look into how these treatments affect patients' bodies (pharmacokinetics), their action on tumors (pharmacodynamics), safety profiles, and initial effectiveness against solid tumors.See study design

What are the potential side effects?

Possible side effects include reactions related to immune system activation such as inflammation in various organs including lungs (pneumonitis), infusion-related reactions similar to allergic responses during drug administration, fatigue due to treatment burden on the body's resources, potential blood disorders affecting cell counts or clotting ability.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My advanced cancer has no standard treatments left or didn't respond to them.

Select...

I agree to a tumor biopsy and have advanced cancer with no standard treatment options.

Select...

I am fully active or can carry out light work.

Timeline

Screening ~ 28 days2 visits

Treatment ~ 6 months6 visits

Follow Up ~ 3 months3 visits

Screening ~ 28 days

Treatment ~ 6 months

Follow Up ~3 months

This trial's timeline: 28 days for screening, 6 months for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Part 1: Frequency of dose-limiting toxicities (DLTs)

Part 2: Objective response rate (ORR)

Secondary outcome measures

Part 1 and Part 2: Area under the concentration-time curve extrapolated to infinity (AUC0-∞) of NDI-101150

Part 1 and Part 2: Area under the concentration-time curve from time zero to the last observable concentration (AUC0-t) of NDI-101150

Part 1 and Part 2: Duration of response (DOR)

+7 more

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183

21%

Fatigue

13%

Nausea

11%

Back pain

Shortness of Breath

Anemia

Abdominal pain

Diarrhea

Pneumonia

Kidney Injury and/or Infection

Dyspnea

Weight Loss

Pneumothorax

Malnutrition, Hypercalcemia and Weakness

Intractable pain, back pain, hip pain

Activated partial thromboplastin time prolonged

Pleural effusion

Atrial fibrillation with rapid ventricular response

Thrombocytopenia

Respiratory failure

Skin rash

colitis

100%

80%

60%

40%

20%

Study treatment Arm

Single Arm

Trial Design

2Treatment groups

Experimental Treatment

Group I: NDI-101150-Pembrolizumab (Combination therapy)Experimental Treatment2 Interventions

Patients in escalation and expansion phase, will receive NDI-101150 capsules orally once daily continuously in 3-week cycles (21 days), along with pembrolizumab via intravenous (IV) infusion at a dose of 200 mg every 3 weeks.

Group II: NDI-101150 (Monotherapy)Experimental Treatment1 Intervention

Patients in escalation and expansion, will receive NDI-101150 capsules orally once daily continuously in 4-week cycles (28 days).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

2017

Completed Phase 2

~2010

0 / 3Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for solid tumors include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy kills rapidly dividing cells, including cancer cells, while targeted therapies inhibit tumor growth by focusing on specific molecular targets such as proteins or genes. Immunotherapy, such as pembrolizumab, boosts the body's immune system to recognize and destroy cancer cells. These mechanisms are vital for solid tumor patients as they provide diverse strategies to combat cancer, potentially improving treatment efficacy and allowing for more personalized approaches.

Innovative agents in multiple myeloma.Towards pathway-centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathway.The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.